publication date: Sep. 22, 2017

In Brief NCI awards $12.4 million lymphoma research grant renewal to University of Iowa and Mayo Clinic

The University of Iowa Holden Comprehensive Cancer Center and Mayo Clinic received a five-year, $12.4 million grant renewal from NCI to continue the Specialized Program of Research Excellence for lymphoma research.

The University of Iowa/Mayo Clinic Lymphoma SPORE is a research collaboration focused on developing new approaches to the prevention, detection, and treatment of lymphoma. First funded in 2002 and competitively renewed in 2007, 2012, and now in 2017, it is the nation’s longest-standing lymphoma SPORE and has now received more than $46 million from NCI.

The SPORE funds support four major research projects, four shared research cores, clinical trials, early pilot projects, and new investigators in lymphoma research taking place at Holden and Mayo.

According to the researchers, reviewers commended multiple components of the University of Iowa/Mayo Clinic collaboration, including a supportive scientific environment in both cancer centers that encourages research that has resulted in more than 150 papers published in the last funding cycle.

The reviewers also noted the SPORE collaboration’s high rate of success in funding productive developmental research work and fostering careers in translational lymphoma research.

The SPORE team’s work includes translational and clinical studies exploring the potential of treatments that stimulate the immune system to treat lymphoma, clinical trials targeting lymphoma-specific signaling pathways, … Continue reading NCI awards $12.4 million lymphoma research grant renewal to University of Iowa and Mayo Clinic

To access this members-only content, please log in.
If you're not a subscriber why not join today?
If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2017 The Cancer Letter Inc.